FDA Fast Tracks Cellceutix’s Oral Mucositis Candidate

Cellceutix has won FDA fast track designation for its Brilacidin-OM, an oral rinse formulation for preventing oral mucositis, a side effect associated with certain cancer treatments.

The candidate is currently in Phase 2 trials in patients undergoing chemoradiation for the treatment of head and neck cancer.